GenomOncology provides the healthcare community with data-driven insights to improve cancer care. GenomOncology strengthens your precision oncology program by transforming valuable, but unusable data, into actionable oncology treatment options and strategic insights to drive measurable results.
Location: United States, Ohio, Cleveland
Employees: 11-50
Total raised: $250K
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | North Coas... | northcoast... |
| - | Venture fo... | venturefor... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.06.2012 | - | $250K | JumpStart |
Mentions in press and media 10
| Date | Title | Description |
| 10.09.2024 | GenomOncology Partners with Precipio to Advance Myeloid Testing and Reporting | CLEVELAND, Sept. 10, 2024 /PRNewswire/ -- September 4th, 2024. GenomOncology, a leading provider of precision medicine software, and Precipio, a specialty cancer diagnostics company, announced their strategic partnership aimed at advancing ... |
| 29.04.2024 | GenomOncology Introduces Expanded Support for Germline Testing in GO Pathology Workbench | CLEVELAND, April 29, 2024 /PRNewswire/ -- GenomOncology (GO) revealed today an upgraded version of GO Pathology Workbench, their software platform for tertiary analysis and reporting of next generation sequencing (NGS) and other molecular t... |
| 05.11.2015 | Congenica and GenomOncology announce collaborative agreement | Congenica and GenomOncology announce collaborative agreement 05-11-2015 Congenica, leader in genomic interpretation and diagnostics in rare genetic disease, and GenomOncology, specialists in precision medicine technology in the field of onc... |
| 18.07.2014 | Personalized medicine: GenomOncology on the “silliness” of reimbursers | Glynias’ rationale: A fair amount of genome sequencing is already taking place in hospitals, academic research labs and companies. More and more research centers have purchased high-throughput sequencing machines (check out this cool world ... |
| 16.07.2014 | Personalized medicine: It may be high cost, but it’s higher value | “The elephant in the room is that 70 percent of the cancer drugs don’t work for their intended use,” said Gerald McDougall, a principal at PriceWaterhouseCoopers Health that focuses on personalized medicine. Because of this, building compan... |
| 06.02.2014 | GenomOncology Receives Investment from TriStar Technology Ventures | GenomOncology, a Westlake, Ohio-based developer of technology that translates next generation sequencing data for clinicians and researchers, received an investment from TriStar Technology Ventures. The amount of the funding was not disclos... |
| 06.06.2012 | GenomOncology Receives $250K in Funding from JumpStart | GenomOncology, a Cleveland, OH-based company developing technology to automate the analysis of sequenced genetic information, has received $250k in funding from JumpStart. The company, which is continuing to raise capital in this current ro... |
| 06.06.2012 | GenomOncology Raises $250K | CLEVELAND, OH, Company developing technology to automate the analysis of sequenced genetic information raised funds from venture development organization, >> Click here for more funding data on GenomOncology >> To export Gen... |
| - | Personalized medicine: GenomOncology on the “silliness” of reimbursers | Personalized medicine is here. But it’s up to insurance carriers to catch up with technology that’s hurtling forward faster and faster, or so says Manuel Glynias, CEO of Cleveland-based GenomOncology, His company is in the business of solvi... |
| - | Personalized medicine: It may be high cost, but it’s higher value | Personalized medicine will be expensive in these early days of pioneering and planning. But individual genomic testing is not going to be exorbitant forever – and the ROI is gonna be big, both in patient outcomes and dollars saved, said a p... |